NuVasive's Attrax Putty has been cleared by the FDA for use in interbody fusions of the thoracolumbar spine, NuVasive said Jan. 5.
The clearance allows the bone void filler to be used with NuVasive's procedurally integrated thoracolumbar interbody portfolio, NuVasive stated in a news release. Attrax Putty is a synthetic, bioactive and osteoconductive bone void filler designed to enable bone formation without added cells or growth factors.
This indication makes the bone void filler the first synthetic biologic cleared for use in interbody fusions of the thoracolumbar spine. It's also supported by a level 1 trial for use in posterolateral spinal fusions.